A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (αIIbβ3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia–like phenotype
- 15 October 2001
- journal article
- case report
- Published by American Society of Hematology in Blood
- Vol. 98 (8) , 2432-2441
- https://doi.org/10.1182/blood.v98.8.2432
Abstract
This article reports a Glanzmann thrombasthenia (GT) patient, N.M., with a point mutation in the third cysteine-rich repeat of beta3-integrin or platelet glycoprotein (GP) IIIa, leading to the expression of a constitutively activated fibrinogen receptor. The diagnosis of GT was based on a severely reduced platelet-aggregation response to a series of agonists and approximately 20% of surface-expressed GPIIb-IIIa. The patient's GPIIb-IIIa constitutively expressed epitopes recognized by antibodies to ligand-induced binding sites (LIBS) and also spontaneously bound the fibrinogen-mimetic antibody, PAC-1. Furthermore, significant amounts of bound fibrinogen were detected on his platelets ex vivo. No signs of platelet activation were observed on sections of unstimulated platelets from N.M. by electron microscopy. Immunogold labeling highlighted the presence of surface-bound fibrinogen but revealed platelet heterogeneity with regard to the surface density. When the patient's platelets were stimulated by thrombin-receptor activating peptide, amounts of surface-expressed GPIIb-IIIa increased and the aggregation response improved, although it failed to normalize. Platelets from N.M. were able to adhere and spread on immobilized fibrinogen. Sequence analysis of genomic DNA from N.M. revealed a homozygous g1776T>C mutation in GPIIIa, leading to a Cys560Arg amino acid substitution. A stable Chinese hamster ovary (CHO) cell line was prepared expressing surface GPIIb-Arg560IIIa. Like platelets from the patient, GPIIb-Arg560IIIa-transfected CHO cells constitutively bound LIBS antibodies and PAC-1. They also showed an enhanced ability to adhere on surface-bound fibrinogen. Overall, these data demonstrate that a gain-of-function mutation can still be associated with a thrombasthenic phenotype even though platelets show spontaneous fibrinogen binding.Keywords
This publication has 74 references indexed in Scilit:
- Integrins Minireview SeriesPublished by Elsevier ,2000
- Homozygous Cys542→Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombastheniaBritish Journal of Haematology, 1999
- Three Novel Integrin β3 Subunit Missense Mutations (H280P, C560F, and G579S) in Thrombasthenia, Including One (H280P) Prevalent in Japanese PatientsBiochemical and Biophysical Research Communications, 1998
- Truncation of the cytoplasmic domain of beta3 in a variant form of Glanzmann thrombasthenia abrogates signaling through the integrin alpha(IIb)beta3 complex.Journal of Clinical Investigation, 1997
- Ultrastructural analysis of the distribution of the vitronectin receptor (α v β 3 ) in human platelets and megakaryocytes reveals an intracellular pool and labelling of the α‐granule membraneBritish Journal of Haematology, 1997
- Stimulation of platelet glycoprotein IIb-IIIa (αIIbβ3-integrin) functional activity by a monoclonal antibody to the N-terminal region of glycoprotein IIIaFEBS Letters, 1996
- A second case of variant of Glanzmann's thrombasthenia due to substitution of platelet GPIII (integrinβ3) Arg214 by TrpHuman Molecular Genetics, 1993
- A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg----214Trp mutation.Journal of Clinical Investigation, 1992
- Integrins: Versatility, modulation, and signaling in cell adhesionCell, 1992
- Integrins: A family of cell surface receptorsCell, 1987